Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T.

Cell. 2003 Nov 26;115(5):523-35.

2.

Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome.

Rodriguez C, Hughes-Davies L, Vallès H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C.

Clin Cancer Res. 2004 Sep 1;10(17):5785-91.

3.

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.

PMID:
21327470
4.

Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.

Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D.

Gynecol Oncol. 2006 Feb;100(2):264-70. Epub 2005 Oct 19.

PMID:
16236351
5.
6.

Expression of EMSY gene in sporadic ovarian cancer.

Altinisik J, Karateke A, Coksuer H, Ulutin T, Buyru N.

Mol Biol Rep. 2011 Jan;38(1):359-63. doi: 10.1007/s11033-010-0116-0. Epub 2010 Mar 28.

PMID:
20349280
7.

Amplification of 11q13 in ovarian carcinoma.

Brown LA, Kalloger SE, Miller MA, Shih IeM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG.

Genes Chromosomes Cancer. 2008 Jun;47(6):481-9. doi: 10.1002/gcc.20549.

PMID:
18314909
8.

Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY.

Raouf A, Brown L, Vrcelj N, To K, Kwok W, Huntsman D, Eaves CJ.

J Natl Cancer Inst. 2005 Sep 7;97(17):1302-6.

PMID:
16145051
9.

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.

Brown LA, Johnson K, Leung S, Bismar TA, Benítez J, Foulkes WD, Huntsman DG.

Breast Cancer Res Treat. 2010 Jun;121(2):347-54. doi: 10.1007/s10549-009-0479-x. Epub 2009 Jul 28.

PMID:
19636701
10.

Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.

Benusiglio PR, Lesueur F, Luccarini C, McIntosh J, Luben RN, Smith P, Dunning A, Easton DF, Ponder BA, Pharoah PD.

BMC Cancer. 2005 Jul 19;5:81.

11.
12.

EMSY links breast cancer gene 2 to the 'Royal Family'.

Yao J, Polyak K.

Breast Cancer Res. 2004;6(5):201-3. Epub 2004 Jul 19.

13.

Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.

Ticha I, Kleibl Z, Stribrna J, Kotlas J, Zimovjanova M, Mateju M, Zikan M, Pohlreich P.

Breast Cancer Res Treat. 2010 Nov;124(2):337-47. doi: 10.1007/s10549-010-0745-y. Epub 2010 Feb 5.

PMID:
20135348
14.

Functional characterization of EMSY gene amplification in human cancers.

Wilkerson PM, Dedes KJ, Wetterskog D, Mackay A, Lambros MB, Mansour M, Frankum J, Lord CJ, Natrajan R, Ashworth A, Reis-Filho JS.

J Pathol. 2011 Sep;225(1):29-42. doi: 10.1002/path.2944. Epub 2011 Jul 7.

PMID:
21735447
15.

A novel BRCA2-binding protein and breast and ovarian tumorigenesis.

King MC.

N Engl J Med. 2004 Mar 18;350(12):1252-3. No abstract available.

PMID:
15028830
16.

Genetic alterations of CCND1 and EMSY in breast cancers.

Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Müller S, Tovey SM, Brown S, Cooke TG, Bartlett JM.

Histopathology. 2008 May;52(6):698-705. doi: 10.1111/j.1365-2559.2008.03007.x. Epub 2008 Apr 2.

PMID:
18393977
17.

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.

Pylkäs K, Erkko H, Nikkilä J, Sólyom S, Winqvist R.

BMC Cancer. 2008 May 26;8:146. doi: 10.1186/1471-2407-8-146.

18.

Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.

Syamala V, Syamala VS, Sreeja L, Raveendran PB, Vijayalekshmi RV, Sheeja VR, Santhi S, Kuttan R, Abraham EK, Ankathil R.

J Exp Ther Oncol. 2008;7(3):227-36.

PMID:
19066131
19.

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.

Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.

Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.

PMID:
22002566
20.

Supplemental Content

Support Center